PDF(Pubmed)
Abstract：
This study evaluated the tolerability and efficacy of the topical rho-kinase inhibitor netarsudil for canine primary corneal endothelial degeneration (PCED). Twenty-six eyes of 21 client-owned dogs with PCED were enrolled in a prospective, randomized, vehicle control clinical trial and received topical netarsudil 0.02% (Rhopressa®) or vehicle control twice daily (BID) for the first 4 months. Then, all patients received netarsudil for the next 4 or 8 months. Complete ophthalmic examination, ultrasonic pachymetry, Fourier-domain optical coherence tomography, and in vivo confocal microscopy were performed at baseline and 1, 2, 4, 6, 8 and 12 months. Effect of netarsudil on central corneal thickness (CCT), percentage of cornea with edema, and endothelial cell density (ECD) were evaluated by repeated measures ANOVA. Kaplan-Meier curves and log-rank test were used to compare corneal edema and clinical progression of eyes in netarsudil versus vehicle control groups. All dogs developed conjunctival hyperemia in at least one eye while receiving netarsudil. Unilateral transient reticulated intraepithelial bullae and stromal hemorrhage were observed respectively in 2 dogs in the netarsudil group. Two dogs showed persistently decreased tear production while receiving netarsudil, requiring topical immunomodulatory treatment. No significant differences in CCT, ECD, corneal edema or clinical progression were observed between netarsudil or vehicle treated eyes. When comparing efficacy of topical netarsudil BID and topical ripasudil 0.4% administered four times daily from our previous study, dogs receiving ripasudil had significantly less progression than those receiving netarsudil.
摘要：
这项研究评估了局部rho激酶抑制剂netarsudil对犬原发性角膜内皮变性（PCED）的耐受性和疗效。21只患有PCED的客户拥有的狗的26只眼睛被纳入了前瞻性研究，随机化，在前4个月,接受局部用netarsudil0.02%(Rhopressa®)或接受溶媒对照(BID)的临床试验。然后，所有患者在接下来的4个月或8个月内均接受netarsudil.完整的眼科检查，超声波测厚仪,傅里叶域光学相干层析成像，在基线和1,2,4,6,8和12个月时进行体内共聚焦显微镜检查.netarsudil对中央角膜厚度（CCT）的影响，角膜水肿的百分比，通过重复测量ANOVA评估和内皮细胞密度（ECD）。使用Kaplan-Meier曲线和对数秩检验比较netarsudil与媒介物对照组的角膜水肿和眼睛的临床进展。所有狗在接受netarsudil时至少一只眼睛出现结膜充血。netarsudil组2只犬分别观察到单侧短暂性网状上皮内大疱和基质出血。两只狗在接受netarsudil时表现出持续减少的泪液产生，需要局部免疫调节治疗。CCT无显著差异,ECD,在netarsudil或媒介物治疗的眼睛之间观察到角膜水肿或临床进展。当比较我们先前的研究中每天四次的局部用奈达舒地尔BID和局部用瑞帕舒地尔0.4％的疗效时，接受rapasudil的狗的进展明显少于接受netarsudil的狗。
